Home/Filings/4/0001104659-21-098784
4//SEC Filing

Ryan Michael Charles 4

Accession 0001104659-21-098784

CIK 0001792581other

Filed

Aug 1, 8:00 PM ET

Accepted

Aug 2, 3:05 PM ET

Size

7.4 KB

Accession

0001104659-21-098784

Insider Transaction Report

Form 4
Period: 2021-07-12
Ryan Michael Charles
Chief Technology Officer
Transactions
  • Other

    Common Stock

    2021-07-13+50,18950,189 total
  • Other

    Restricted Stock Units

    2021-07-12+31,99131,991 total
    Common Stock (31,991 underlying)
Footnotes (3)
  • [F1]The securites were acquired pursuant to a Membership Interest Purchase Agreement dated as of June 14, 2021 among Kiromic Biopharma, Inc., InSilico Solutions, LLC and Michael Ryan.
  • [F2]Each restricted stock unit is the economic equivalent of one share of Kiromic Biopharma, Inc. common stock.
  • [F3]The vesting schedule is such that 25% of the RSUs vest on June 30, 2022, and the remainder will vest at a rate of 1/36th per month for 36 months thereafter.

Issuer

Kiromic Biopharma, Inc.

CIK 0001792581

Entity typeother

Related Parties

1
  • filerCIK 0001875002

Filing Metadata

Form type
4
Filed
Aug 1, 8:00 PM ET
Accepted
Aug 2, 3:05 PM ET
Size
7.4 KB